Overslaan en naar de inhoud gaan

 Alle verbonden artikelen

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Auteurs : Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, OMeara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, vant Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, Van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR
Jaar : 2019
Journal : Nature

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Jaar : 2019
Journal : Ann Oncol
Volume : 30
Pagina's : 1018

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Jaar : 2019
Journal : Ann Oncol
Volume : 30
Pagina's : 1180

Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?

Auteurs : Brandão M, Coens C, Ignatiadis M
Jaar : 2019
Journal : Ann Oncol
Volume : 30
Pagina's : 1677-1681

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Auteurs : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart-Gebhart M, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Jaar : 2019
Journal : J Clin Oncol
Volume : 37
Pagina's : 559-569

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.

Auteurs : Brandão M, Caparica R, Eiger D, de Azambuja E
Jaar : 2019
Journal : Ann Oncol
Volume : 30 Suppl 10
Pagina's : x27-x42

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.

Auteurs : Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, Richard F, Delorenzi M, Sotiriou C, Desmedt C, Lorusso G, Rüegg C
Jaar : 2019
Journal : Oncogene
Volume : 38
Pagina's : 2814-2829

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.

Auteurs : Nederlof I, De Bortoli D, Bareche Y, Nguyen B, de Maaker M, Hooijer GKJ, Buisseret L, Kok M, Smid M, Van den Eynden GGGM, Brinkman AB, Hudecek J, Koster J, Sotiriou C, Larsimont D, Martens JWM, Van de Vijver MJ, Horlings HM, Salgado R, Biganzoli E, Desmedt C
Jaar : 2019
Journal : Breast Cancer Res
Volume : 21
Pagina's : 151

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Auteurs : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Jaar : 2019
Journal : Cancer
Volume : 125
Pagina's : 307-316

Systemic treatment of patients with early breast cancer: recent updates and state of the art.

Auteurs : Caparica R, Brandão M, Piccart-Gebhart M
Jaar : 2019
Journal : Breast
Volume : 48 Suppl 1
Pagina's : S7-S20

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).

Auteurs : Risi E, Biagioni C, Benelli M, Migliaccio I, McCartney A, Bonechi M, Guarducci C, Hilbers F, Di Cosimo S, Huober J, Romagnoli D, Boccalini G, Vitale S, Sotiriou C, Biganzoli L, Di Leo A, Malorni L
Jaar : 2019
Journal : Ther Adv Med Oncol
Volume : 11
Pagina's : 1758835919891608

CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.

Auteurs : Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, Del Genio C, Canfield K, DiRenzo J, Wells W, Gaur A, Robey RB, Guo JY, Powles RL, Sotiriou C, Pusztai L, Febbraio M, Cheng C, Kinlaw WB, Kurokawa M
Jaar : 2019
Journal : Cell Rep
Volume : 29
Pagina's : 3405-3420.e5

Mammaprint™: a comprehensive review.

Auteurs : Brandão M, Pondé N, Piccart-Gebhart M
Jaar : 2019
Journal : Future Oncol
Volume : 15
Pagina's : 207-224

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Auteurs : Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, Rothé F, Willard-Gallo K, Haller A, Ninane V, Burny A, Sculier JP, Spira A, Galon J
Jaar : 2019
Journal : Nature
Volume : 571
Pagina's : 570-575

MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries.

Auteurs : Alexandri C, Stamatopoulos B, Rothé F, Bareche Y, Devos M, Demeestere I
Jaar : 2019
Journal : Sci Rep
Volume : 9
Pagina's : 9636

Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.

Auteurs : Matikas A, Zerdes I, Lövrot J, Richard F, Sotiriou C, Bergh J, Valachis A, Foukakis T
Jaar : 2019
Journal : Clin Cancer Res
Volume : 25
Pagina's : 5717-5726

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.

Auteurs : Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M
Jaar : 2019
Journal : ESMO Open
Volume : 4
Pagina's : e000515

SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.

Auteurs : Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W
Jaar : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pagina's : 16

Denosumab in early-stage breast cancer.

Auteurs : Brandão M, Debiasi M, de Azambuja E
Jaar : 2019
Journal : Lancet Oncol
Volume : 20
Pagina's : e234-e235

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Auteurs : Kirschbrown WP, Kågedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, Von Minckwitz G, Bines J, Garg A
Jaar : 2019
Journal : Cancer Chemother Pharmacol
Volume : 83
Pagina's : 1147-1158